title: Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.
abstract: Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the current evidence based medicine regarding available therapies for SSc-ILD ; discusses the lessons learned from recent SSc-ILD randomized controlled trials (RCTs); and proposes outcome measures and recommendations for design of future RCTs for SSc-ILD.
authors.affiliation: Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
authors.forename: Dinesh
authors.initials: D
authors.lastname: Khanna
authors.forename: James R
authors.initials: JR
authors.lastname: Seibold
authors.forename: Athol
authors.initials: A
authors.lastname: Wells
authors.forename: Oliver
authors.initials: O
authors.lastname: Distler
authors.forename: Yannick
authors.initials: Y
authors.lastname: Allanore
authors.forename: Chris
authors.initials: C
authors.lastname: Denton
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Furst